Everest Group's Vinod Gupta Honored by President of India with Honorary Doctorate for IIT Jodhpur
The Honorable President of India, in her capacity as the Visitor of the Indian Institute of Technology Jodhpur, on recommendation of the Board of Governors of IIT Jodhpur have approved the conferment of the Honorary Degree of Doctor of Science (Honoris Causa) to Vinod Gupta, Managing General Partner at Everest Group.
The convocation of IIT Jodhpur is scheduled on November 21, 2023 in the Permanent Campus of IIT Jodhpur. Dr. K. Radhakrishnan, Former Chairman-ISRO & Former Chairman, Space Commission, has kindly consented to be the Chief Guest of the Convocation ceremony. Mr. Gupta's outstanding contributions have earned him this prestigious recognition. We believe Mr. Gupta's presence will inspire our academic community and this will be a momentous occasion for IIT Jodhpur as this is the first time IIT Jodhpur is conferring the Honorary Doctor Degree to eminent personalities.
Mr. Gupta also has been honored by a Honorary Doctorate from the University of Nebraska and I.I.T., Kharagpur.
Mr. Gupta recognizes the role of education in developing the leaders of tomorrow. Through his charitable foundation, he has helped advance education across fields including: business, science, information technology, communications, intellectual property law and wildlife preservation.
To see actual letter and more information, visit www.gefusa.org
POSaBIT Systems Corporation (the "Company" or "POSaBIT") announces today that the Company is anticipating a delay in filing its annual financial statements and accompanying management's discussion and analysis for the year ended December 31, 2023...
Recently, at Auto China 2024, Neusoft Corporation (Neusoft, SSE:600718) launched OneCoreGo® Global In-Vehicle Intelligent Mobility Solutions 5.0, showcasing its innovative achievements in the AI+ Automotive field. It's also one of the series of...
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor...
Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective...
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger...
bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder...
